Korro Bio’s (KRRO) Buy Rating Reiterated at HC Wainwright

Korro Bio (NASDAQ:KRRO)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $115.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 384.82% from the stock’s previous close.

KRRO has been the subject of a number of other reports. Royal Bank of Canada cut their price target on Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a report on Wednesday. Oppenheimer started coverage on shares of Korro Bio in a research note on Friday, January 10th. They issued an “outperform” rating and a $155.00 target price for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $142.57.

Korro Bio Price Performance

Shares of KRRO stock opened at $23.72 on Thursday. Korro Bio has a 12-month low of $18.50 and a 12-month high of $98.00. The firm has a 50-day moving average price of $30.42 and a 200 day moving average price of $41.70.

Korro Bio (NASDAQ:KRRO) last announced its earnings results on Tuesday, March 18th. The company reported ($2.26) EPS for the quarter, topping the consensus estimate of ($2.33) by $0.07. The business had revenue of $2.27 million during the quarter. On average, research analysts predict that Korro Bio will post -9.52 EPS for the current year.

Hedge Funds Weigh In On Korro Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AlphaQuest LLC lifted its stake in shares of Korro Bio by 23.2% in the 4th quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after purchasing an additional 412 shares during the period. Bank of New York Mellon Corp boosted its stake in Korro Bio by 3.0% during the 4th quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company’s stock worth $563,000 after acquiring an additional 435 shares during the last quarter. Bank of America Corp DE grew its holdings in Korro Bio by 9.0% during the fourth quarter. Bank of America Corp DE now owns 7,037 shares of the company’s stock valued at $268,000 after purchasing an additional 581 shares during the period. Rhumbline Advisers increased its stake in Korro Bio by 7.8% in the fourth quarter. Rhumbline Advisers now owns 9,602 shares of the company’s stock valued at $366,000 after purchasing an additional 691 shares in the last quarter. Finally, Blair William & Co. IL raised its holdings in Korro Bio by 5.7% in the fourth quarter. Blair William & Co. IL now owns 12,895 shares of the company’s stock worth $491,000 after purchasing an additional 695 shares during the period. 13.18% of the stock is owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).